



Praxair's Docket No. MPI00-452P1RM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: O'Keefe, Theresa et al.

Application No.: 10/060,714

Group No.: 1644

Filed: January 30, 2002

Examiner: Schwardon, Ronald B.

For: HYBRID ANTIBODIES AND USES THEREOF

**Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. [x] Preliminary Statements
2. [x] Copy of Listed Information Item Accompanying This Statement (A41, B37, C3-C5)
3. [x] Forms PTO/SB/08A and PTO/SB/08B (substitute for Form PTO-1449)

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Address"
Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker/Beverly Sotiropoulos
(type or print name of person certifying)

Date: December 6, 2004

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Preliminary Statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Copies of Listed Information Items Accompanying This Statement

Legible copies of the items listed in Form PTO/SB/08A and Form PTO/SB/08B (substitute for Form PTO-1449) accompany this information statement.

December 6, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By Tracy M. Sioussat

Tracy M. Sioussat, Ph.D.
Registration No. 50,609
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-374-7679
Facsimile - 617-551-8820



Practitioner Docket No. MPI00-452P1RM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: O'Keefe, Theresa et al.

Application No.: 10/060,714 Group No.: 1644

Filed: January 30, 2002 Examiner: Schwardon, Ronald B.

For: HYBRID ANTIBODIES AND USES THEREOF

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed:

Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

(1) a final action under Section 1.113,
(2) a notice of allowance under Section 1.311, or

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"
Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.


Beverly Sotropoulos
Signature

Sean Hunziker/Beverly Sotropoulos
(type or print name of person certifying)

Date: December 6, 2004

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI00-452P1RM

(3) an action that otherwise closes prosecution in the application

whichever occurs first.

[] Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

[] Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

[] No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

OR

[] The information disclosure statement transmitted herewith is being filed *after* a final action under Section 1.113, or a notice of allowance under Section 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.

[] In accordance with the requirements of 37 C.F.R. Section 1.97(d):

A. [] Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

B. [] Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

C. [] No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

Practitioner's Docket No. **MPI00-452P1RM**

FEE PAYMENT

3. The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

Applicant believes no fee is due in connection with this submission. However, if any fees are due, please charge Account 501668.

Fee due \$0.00

METHOD OF PAYMENT OF FEE

4. Attached is a check in the amount of \$ _____.

Charge Account No. 501668 in the amount of \$00.


A duplicate of this request is attached.

If any fees are due, please charge Account 501668.

December 6, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By Tracy M. Sioussat
Tracy M. Sioussat, Ph.D.
Registration No. 50,609
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-374-7679
Facsimile - 617-551-8820



Please type a plus sign (+) inside this box → +

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DEC 08 2004

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

88

O P E R A T I O N S
Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

DEC 08 2001



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/060,714
Filing Date	January 30, 2002
First Named Inventor	O'Keefe, Theresa
Group Art Unit	1644
Examiner Name	Schwadron, Ronald B.
Attorney Docket Number	MPI00-452P1RM

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	C3	A.P. Lewis et al., "Generation of Humanized Monoclonal Antibodies by 'Best Fit' Framework Selection and Recombinant Polymerase Chain Reaction," <i>The Year in Immunology</i> , Vol. 7 (1993) pp 110-118	
	C4	M. Little et al., "Of Mice and Men: Hybridoma and Recombinant Antibodies," <i>Immunology Today</i> , Vol. 21, No. 8 (Aug. 1, 2000) pp 364-370	
	C5	G. Winter et al., "Humanized Antibodies," <i>Immunology Today</i> , Vol. 14, No. 6 (1993) pp 243-246	

Examiner Signature		Date Considered
--------------------	--	-----------------

Did not receive any NPLs.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.